How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review
Open Access
- 1 April 2010
- journal article
- review article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (4), 933-943
- https://doi.org/10.1038/jid.2009.391
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- A critical assessment of composite and coprimary endpoints: A complex problemJournal of the American Academy of Dermatology, 2008
- Critical Review of Generic and Dermatology-Specific Health-Related Quality of Life InstrumentsJournal of Investigative Dermatology, 2007
- A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global AssessmentBritish Journal of Dermatology, 2006
- Psoriasis assessment tools in clinical trialsAnnals Of The Rheumatic Diseases, 2005
- The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severityBritish Journal of Dermatology, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- A quantitative definition of severe psoriasis for use in clinical trialsJournal of Dermatological Treatment, 2004
- Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their qualityBritish Journal of Dermatology, 1999
- Understanding and evaluating clinical trialsJournal of the American Academy of Dermatology, 1996
- The Self-Administered Psoriasis Area and Severity Index Is Valid and ReliableJournal of Investigative Dermatology, 1996